What does the source actually show?

Match the study to the claim

• Was the work done in people, animals or cells, the body’s tiny living parts tested in a laboratory?
• Was the exact product being offered tested?
• Was it used for the same health problem?
• What was compared, and what changed?
• What does the study leave unanswered?

A trial is a study that tests a treatment. Ask the medical professional treating you to explain who took part and how the results relate to the proposed care.

If the title is hard to read, request a plain explanation of the result and its limits. A link list does not give that explanation.

Separate product review from research interest

A pharmacist, doctor or registered facility prepares a compounded medicine to order.

FDA is the federal medicine agency, short for Food and Drug Administration.

For compounded medicines, FDA provides no review of benefit, harm or quality before marketing, as of September 2026.

For several proposed peptide ingredients, FDA has limited information about harm in people.

It warns that the body’s defences may react to the injected substance or unwanted material in it, called impurities.

FDA does not have enough information to know whether these products would harm people.

Ask what is known for the exact product and what remains uncertain.

Read the type of official document

An FDA advisory committee is a group asked to advise the agency.

A warning letter states FDA’s concerns about a seller at the time it was written.

FDA and that seller may exchange more information afterward, which can change FDA’s view of the problems described.

Check for a later response or a letter closing the matter.

An advisory committee’s vote is advice; it does not itself change compounding rules, as of September 2026.

By September 2026, no official vote record from FDA’s July peptide-compounding meeting had been published by FDA.

Ask for a current final decision when a headline claims a rule changed.